PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity

Pharmacogenetics and Genomics

Volumn 16, Issue 3, 2006, Pages 183-190

  Furlong, Clement E ^a   Holland, Nina ^b   Richter, Rebecca J ^a   Bradman, Asa ^b   Ho, Alan ^b   Eskenazi, Brenda ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Chlorpyrifos; Diazinon; Latino cohort; Paraoxonase 1 (PON1); PON1 status; Pregnancy

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHLORPYRIFOS; ORGANOPHOSPHATE INSECTICIDE; PARAOXON; PHENYLACETIC ACID;

AGRICULTURAL WORKER; ARTICLE; COHORT ANALYSIS; DRUG SENSITIVITY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FEMALE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MOTHER; MOUSE; NEWBORN; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AGRICULTURE; ANIMALS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; COHORT STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; MOTHERS; OCCUPATIONAL EXPOSURE; ORGANOPHOSPHORUS COMPOUNDS; PHARMACOGENETICS; PHENYLACETATES; PHOSPHORIC ACID ESTERS; POLYMORPHISM, GENETIC;

MUS MUSCULUS;

EID: 33644604127     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Barr D, Bravo R, Weerasekera G, Caltabiano L, Whitehead R. Concentrations of dialkyl phosphate metabolites of organophosphorus pesticides in the US population. Environ Health Perspect 2004; 112:186-200.
2. Hill RH Jr, Head SL, Baker S, Gregg M, Shealy DB, Bailey SL, et al. Pesticide residues in urine of adults living in the United States: reference range concentrations. Environ Res 1995; 71:99-108.
3. Loewenherz C, Fenske RA, Simcox NJ, Bellamy G, Kalman D. Biological monitoring of organophosphorus pesticide exposure among children of agricultural workers in central Washington State. Environ Health Perspect 1997; 105:344-353.
4. Simcox NJ, Camp J, Kalman D, Stebbins A, Bellamy G, Lee IC, Fenske R. Farmworker exposure to organophosphorus pesticide residues during apple thinning in central Washington State. Am Ind Hyg Assoc J 1999; 60:752-761.
5. Berkowitz GS, Obel J, Deych E, Lapinski R, Godbold J, Liu Z, et al. Exposure to indoor pesticides during pregnancy in a multiethnic, urban cohort. Environ Health Perspect 2003; 111:79-84.
6. Whyatt RM, Barr DB, Camann DE, Kinney PL, Barr JR, Andrews HF, et al. Contemporary-use pesticides in personal air samples during pregnancy and blood samples at delivery among urban minority mothers and newborns. Environ Health Perspect 2003; 111:749-756.
7. Eskenazi B, Bradman A, Gladstone EA, Jaramillo S, Birch K, Holland NT. CHAMACOS: a longitudinal birth cohort study: lessons from the fields. J Child Health 2003; 1:3-27.
8. Bradman A, Eskenazi B, Barr DB, Bravo R, Castorina R, Chevrier J, et al. Organophosphate urinary metabolite levels during pregnancy and after delivery in women living in an agricultural community. Environ Health Perspect 2005; doi: 101289/ehp.7894 [Epub ahead of print].
9. Bradman A, Barr DB, Claus Henn BG, Drumheller T, Curry C, Eskenazi B. Measurement of pesticides and other toxicants in amniotic fluid as a potential biomarker of prenatal exposure: a validation study. Environ Health Perspect 2003; 111:1782-1789.
10. Castorina R, Bradman A, McKone TE, Barr DB, Harnly ME, Eskenazi B. Cumulative organophosphate pesticide exposure and risk assessment among pregnant women living in an agricultural community: a case study from the chamacos cohort. Environ Health Perspect 2003; 111:1642-1648.
11. Fenske RA, Lu C, Barr D, Needham L. Children's exposure to chlorpyrifos and parathion in an agricultural community in central Washington State. Environ Health Perspect 2002; 110:549-553.
12. USEPA 2000. Chlorpyrifos revised risk assessment and agreement with registrants. http://www.epa.gov/pesticides/op/chlorpyrifos/agreement.pdf
13. USEPA 2001. Diazinon revised risk assessment and agreement with registrants. http://www.epa.gov/pesticides/op/diazinon/agreement.pdf
14. Sherman JD. Organophosphate pesticides - neurological and respiratory toxicity. Toxicol Ind Health 1995; 11:33-39.
15. Eskenazi B, Bradman A, Castorina R. Exposures of children to organophosphate pesticides and their potential adverse health effects. Environ Health Perspect 1999; 107 (Suppl 3):409-419.
16. Young JG, Eskenazi B, Gladstone EA, Bradman A, Pedersen L, Johnson C, et al. Association between in utero organophosphate pesticide exposure and abnormal reflexes in neonates. Neurotoxicology 2005; 26:199-209.
17. Garcia SJ, Seidler FJ, Slotkin TA. Developmental neurotoxicity of chlorpyrifos: targeting glial cells. Env Toxicol Pharmacol 2005; 19:455-461.
18. Moser VC, Padilla S. Age-and gender-related differences in the time-course of behavioral and biochemical effects produced by oral chlorpyrifos in rats. Toxicol Appl Pharmacol 1998; 149:107-119.
19. Sheets L. A consideration of age-dependent differences in susceptibility to organophosphorus and pyrethroid insecticides. Neurotoxicology 2000; 21:57-63.
20. Padilla S, Buzzard J, Moser VC. Comparison of the role of esterases in the differential age-related sensitivity to chlorpyrifos and methamidophos. Neurotoxicology 2000; 21:49-56.
21. Zheng Q, Olivier K, Won YK, Pope CN. Comparative cholinergic neurotoxicity of oral chlorpyrifos exposures in preweanling and adult rats. Toxicol Sci 2000; 55:124-132.
22. Pope CN, Chakraborti TK, Chapman ML, Farrar JD, Arthun D. Comparison of in vivo cholinesterase inhibition in neonatal and adult rats by three organophosphorothioate insecticides. Toxicology 1991; 68:51-61.
23. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 2003; 111:1403-1409.
24. Cole T, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, et al. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 2003; 13:357-364.
25. Ecobichon DJ, Stephens DS. Perinatal development of human blood esterases. Clin Pharmacol Ther 1973; 14:41-47.
26. Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet 1983; 35:393-408.
27. Augustinsson K, Barr M. Age variation in plasma arylesterase activity in children. Clin Chim Acta 1963; 8:568-573.
28. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14:334-336.
29. Furlong CE, Costa LG, Hassett C, Richter RJ, Adler DA, Disteche CM, et al. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact 1993; 87:35-48.
30. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 1991; 30:10141-10149.
31. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19:2214-2225.
32. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3:73-76.
33. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598-608.
34. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000; 10:767-779.
35. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory region polymorphisms on paraoxonase (PON1) expression. Am J Hum Genet 2001; 68:1428-1436.
36. Deakin S, Leviev I, Brulhart-Meynet M-C, James RW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position 107, implicating the Sp1 transcription factor. Biochem J 2003; 372:643-649.
37. Suehiro T, Nakamura T, lnoue M, Shiinoki T, Ikeda Y, Kumon Y, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000; 150:295-298.
38. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993; 40:337-346.
39. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9:745-753.
40. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441-2447.
41. Jarvik GP, Jampsa R, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA, Furlong CE. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 2003; 13:291-295.
42. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 2001; 42:528-535.
43. Main AR. The role of A-esterase in the acute toxicity of paraoxon, TEPP and parathion. Can J Biochem Physiol 1956; 34:197-216.
44. Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol 1990; 103:66-76.
45. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 1989; 180:242-247.
46. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287.
47. Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 1995; 76:219-226.
48. Cole T, Walter B, Shih D, Tward A, Lusis AJ, Timchalk C, et al. Toxicity of chlorpyriphos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genom 2005; 15:589-598.
49. Brophy VH, Jarvik GP, Furlong C. PON1 polymorphisms. In: Costa LG, Furlong C, editors. Paraoxonase (PON1) in health and disease: basic and clinical aspects. Boston, Massachusetts: Kluwer Academic Press; 2002. pp. 53-77.
50. DPR. Pesticide Use Reporting 2001 Summary Data: Department of Pesticide Regulation. Sacramento, California: California Environmental Protection Agency; 2002.
51. Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, Barr DB, et al. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect 2004; 112:1116-1124.
52. Richter R, Jampsa R, Jarvik GP, Costa LG, Furlong CE. Determination of paraoxonase 1 (PON1) status and genotypes at specific polymorphic sites. Curr Protoc Toxicol 2004; 4.12.1-4.12.19.
53. Blatter-Garin M-C, Abbot C, Messmer S, Mackness MI, Durrington P, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994; 304:549-554.
54. StataCorp. Stata Statistical Software: release 8.0. College Station, Texas: Stata Corporation; 2003.
55. Berkowitz GS, Wetmur JG, Birman-Deych E, Obel J, Lapinski RH, Godbold JH, et al. In-utero exposure, maternal paraoxonase activity and head circumference. Environ Health Perspect 2004; 112:338-391.
56. Burlina A, Michielin E, Galzinga L. Characteristics and behaviour of arylesterase in human serum and liver. Eur J Clin Invest 1977; 7:17-20.
57. Yuknavage KL, Fenske RA, Kalman DA, Keifer MC, Furlong CE. Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. J Toxicol Env Health 1997; 51:35-55.
58. California EPA 2002. Pesticide use reporting 2001 Summary data. http://www.cdpr.ca.gov/docs/pur/pur01rep/01_pur.htm
59. Huff R, Abou-Donia MB. In vitro effect of chlorpyrifos oxon on muscarinic receptors and adenylate cyclase. Neurotoxicology 1995; 16:281-290.
60. Li W-F. Dissertation: development of a mouse model for studying paraoxonase. Seattle, Washington: University of Washington, School of Public Health and Community Medicine, Department of Environmental Health; 1993.
61. Li W-F, Matthews C, Disteche CM, Costa LG, Furlong CE. Paraoxonase (Pon1) gene in mice: sequencing, chromosomal location and developmental expression. Pharmacogenetics 1997; 7:137-144.
62. Moser VC, Chanda SM, Mortensen SR, Padilla S. Age- and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities. Toxicol Sci 1998; 46:211-222.
63. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, Satoh T. Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metabol Dispos 1995; 23:1022-1027.
64. Wetmur JG, Kumar M, Zhang L, Palomeque C, Wallenstein S, Chen J. Molecular haplotyping by linking emulsion PCE: analysis of paraoxonase 1 haplotypes and phenotypes. Nucleic Acids Res 2005; 33:2615-2619.
65. Timchalk C, Poet TS, Hinman MN, Busby AL, Kousba AA. Pharmacokinetic and pharmacodynamic interaction for a binary mixture of chlorpyrifos and diazinon in the rat. Toxicol Appl Pharmacol 2005; 205:31-42.
66. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46:1239-1247.
67. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Atherscler Thromb Vasc Biol 2001; 21:1451-1457.
68. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Rad Biol Med 2004; 37:1317-1323.
69. Ozer EA, Pezzulo A, Shih DM, Chun C, Furlong C, Lusis AJ, et al. Human and murine paraoxonase 1 are host modulators of P. aeruginosa quorum-sensing. FEMS Microbiol Lett 2005; in press.